Essential blepharospasm and hemifacial spasm: Characteristic of the patient, botulinum toxin A treatment and literature review;Blefarospasmo essencial e espasmo hemifacial: Características dos pacientes, tratamento com toxina botulínica A e revisão da literatura

Arquivos Brasileiros de Oftalmologia

Volumn 69, Issue 1, 2006, Pages 23-26

  Schellini, Silvana Artioli ^a   Matai, Olívia ^a   Igami, Thais Zamudio ^a   Padovani, Carlos Roberto ^a   Padovani, Carlos Pereira ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Action potentials; Blepharospasm drug therapy; Botulinum toxin type A therapeutic use; Hemifacial spasm drug therapy; Oculomotor muscles

Indexed keywords

BOTULINUM TOXIN A;

ADULT; BLEPHAROSPASM; CHEEK MUCOSA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRY EYE; FEASIBILITY STUDY; FEMALE; GENDER; HEMIFACIAL SPASM; HUMAN; MALE; PTOSIS; REVIEW; TREATMENT OUTCOME;

EID: 33746359326     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492006000100005     Document Type: Review

References (42)

1. Faulstich ME, Carnrike CL Jr, Williamson DA. Blepharospasm and Meige syndrome: a review of diagnostic, aetiological and treatment approaches. J Psychosomat Res. 1985;29(1):89-94.
2. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998;129(3):221-8.
3. Elston JS, Marsden CD, Grandas F, Quinn NP. The significance of ophthalmological symptoms in idiopathic blepharospasm. Eye. 1998;2(Pt 4):435-9.
4. Grandas F, Elston J, Quinn NP, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychol. 1998;51(6):767-72.
5. Broocks A, Thiel A, Angenstein D, Dressler D. Higher prevalence of obsessive-compulsive symptoms in patients with blepharospasm than in patients with hemifacial spasm. Am J Psychiatry. 1998;155(4):555-7.
6. Sachdev P. Tardive blepharospasm. Mov Disord. 1998;13(6):947-51.
7. Levin H, Reddy R. Clozapine in the treatment of neuroleptic-induced blepharospasm: a report of 4 cases. J Clin Psychol. 2000;61(2):140-3.
8. Tan NC, Chan LL, Tan EK. Hemifacial spasm and involuntary find movements. QJM. 2002;95(8):493-500.
9. Fruch BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol. 1984;102(10):1464-8.
10. Tsoy EA, Buckley EG, Dutton JJ. Treatment of blepharospasm with botulinum toxin. Am J Ophthalmol. 1985;99(2):176-9.
11. Mauriello JA Jr, Dhillon S, Leone T, Pakeman B, Mostafavi R, Yepes MC. Treatment selections of 239 patien with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol. 1996;80(12):1073-6.
12. Cibis GW, Waeltermann J. Botulinum. isn't just a poison anymore. Botalinum toxin in treatment of strabismus and essential blepharospasm. Mo Med. 1985; 82(3):145-7.
13. Kohler A, Ochsner F. Current indications for the treatment with botulinum toxin. Rev Med Suisse Romande. 2001;121(6):471-4.
14. Zajacz M. [Applications of the botulinum A toxin]. Orvosi Hetilap. 2003; 144(18):837-42. Hungarian.
15. Johnson EA. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol. 1999;53:551-75.
16. Singer C. [Indications and management of botulinum toxin]. Rev Neural. 1999; 29(2):157-62. Spanish.
17. Sarrabayrouse MA. Indications and limitations for the use of botulinum toxin for the treatment of facial wrinkles. Aesthetic Plast Surg. 2002;26(4):233-8.
18. Binder WJ, Blitzer A. Brin MF. Treatment of hyperfunctional fines of the face with botulinum toxin A. Dermatol Surg. 1998;24(11):1198-205.
19. Horwath-Winter J, Bergloeff J, Floegel I. Haller-Schober EM, Schmut O. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol. 2003;87(1):54-6.
20. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103(3):347-50.
21. McCann JD, Gauthier M, Morschbacher R. Goldberg RA, Anderson RL, Fine PG, et al. A novel mechanism for benign essential blepharospum. Ophthal Plast Reconstr Surg. 1999;15(6):384-9.
22. Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Correia AP, et al. Dysbot: a single blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two furmulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord. 1997;12(6):1013-8.
23. Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol. 1985;99(5):542-6.
24. Mackie IA. Riolan's muscle: action and indications for botulinum toxin injection. Eye. 2000,14(Pt 3A):347-52.
25. Jankovic J. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychol. 1995;59(3):309-11.
26. Jankovic J. Pretarsal application of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychol. 1996;60(6):704-7.
27. Cakmur R, Ozturk V, Uzurel F, Donmez B, Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospam and hemifacial spasm J Neurol. 2002;249(1):64-8.
28. Snir - Young JDH. Handbook of Botulinum Toxin Treatment. Br J Ophthalmol. 1996;80(9):854.
29. Andrade LA, Borges V, Ferraz HB, Azevedo-Silva SM. [Bolutinum toxin A: experience in the treatment of 115 patients]. Arq Neuropsiquiatr. 1997;55(3B): 553-7. Portuguese.
30. Chang LB, Tsai CP, Liao KK, Kao KP, Yuan CL, Yen DJ, et al. Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm. Zhonghua Yi Xue Za Zhi. (Taipei). 1999;62(1)1:-5.
31. Wang J. Lin S, Zhang X. [Blepharospasm and hemifacial spasm treated with botulinum A toxin injection]. Zhonghua Er Bi Yan Hou Ke Za Zhi. 1998;33(5):291-3. Chinese
32. Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present and future. Ophthal Plast Reconstr Surg. 1998;14(5):305-17.
33. Chen RS, Lu CS, Tsai CH. Botulinum toxin A injection in the treatment of hemifacial spasms. Acta Neurol Scand. 1996.94(3):207-11.
34. Thussu A, Barman CR, Prabhakar S. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation. Neurol India. 1999; 47(3):206-9.
35. Cardoso F. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A]. Arq Neuropsiquiatr. 2003;61(3A):607-10. Portuguese.
36. Osaki MH, Belfort Jr R. Qualidade e vida e custos diretos em pacientes com blefarospasmo essencial c espasmo hemifacial, tratados com toxima botulínica. Arq Bras Oftalmol. 67(1):43-9.
37. Schnider P, Birner P, Moraru F, Auff E. [Long-term treatment with botulinum toxin: dosage, treatment schedules and costs). Wiener Klin Wochensch. 1999; 111(2):59-65. German.
38. Bigalke H, Wohlfarth K, Irmer A. Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol. 2001;168(1):162-70.
39. Tucha O, Naumann M, Berg D, Alders GL, Lang KW. Quality of life in patients with blepharospasm. Acta Neurol Scand. 2001;103(1):49-52.
40. Bradley EA, Hodge DO, Bartley GB. Benign essential blepharospasm among residents of Olmsted County, Minnesota, 1976 to 1995: an epidemiologic study. Ophthal Plast Reconstr Surg. 2003;19(3):177-81.
41. Cunha MC, Aguirre OP, Souza-Dias CR. Tratamento do espasmo facial unilateral com toxina botulínica tipo A. Arq Bras Oftalmol. 1998;61(1):54-60.
42. Calace P, Cortese G, Piscopo P, Della Volpe G, Gagliardi V, Magli A, et al. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol. 2003;13(4):331-6.